Posts related to ‘Newsletter’

Russia: Oil Prices Are Going Back Down

oil8Falling oil prices are particularly bad for Russia. A large part of the country’s GDP comes from exporting its vast supply of crude and gas.

So, it is especially surprising that a senior Russian official is predicting that oil will fall again after advancing above $50 recently. Read More »

Posted on: March 24, 2009 – 5:12 am in Economy, International Markets, Newsletter, Oil & Gas

The Woman Who Predicted The Mortgage Crisis Goes On The Record About The Future

A WVFC interview with Deutsche Bank’s Karen Weaver
by Elaine Lafferty

We kept hearing about this woman named Karen Weaver, a top Wall Street analyst, who correctly sounded the alarm three years ago about the subprime mortgage crisis that has shaken the global economy (PDF) to its core. If only Wall Street and the banking industry had listened.

Today, Weaver is a Managing Director and the Global Head of Securitization Research, responsible for Deutsche Bank’s research on securitized fixed-income products. She also manages Deutsche Bank Research-Americas, which has 300 professionals covering economics, debt and equity markets. Weaver joined Deutsche Bank from Credit Suisse First Boston in 2000. Prior to joining CSFB, she was a portfolio manager active in the ABS and MBS markets.

We asked Weaver — who everybody listens to now — for her thoughts on the economy and the future:

The interview continues here.

Posted on: April 30, 2008 – 5:49 pm in Housing, Newsletter

Biotech Business Daily (BTRX, BMRN, DSCO, ENDP, MNKD, MIPI, QSC, TECH)

Today almost feels like the "March of Biotech-inguins" because most of the movers were small companies you might otherwise miss.  Here were the big movers:

  • Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
  • Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
  • Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
  • Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
  • Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
  • Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
  • Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008

Posted on: April 30, 2008 – 3:21 pm in Biotech, Newsletter, , , , , , , ,

Select Analyst Calls (Nov. 7, 2006)

ADBE started as Equal Weight at Morgan Stanley.ADSK started as Equal Weight at Morgan Stanley.AHO cut to Underweight at JPMorgan.AMTD started as Neutral at Prudential.ANN cut to Mkt Perform at FBR.AWR cut to Neutral at UBS.BGO cut to Sector Perform at RBC.BMR cut to Mkt Perform at Wachovia.BSX reitr Buy at Jefferies.CBF started as Buy at Citigroup.CTXS started as Equal Weight at Morgan Stanley.ET started as Overweight at Prudential.GGP cut to Underperform at RBC.HCN started as Buy at Cantor Fitzgerald.HRB raised to Buy at Soleil.ICFI started as Buy at Jefferies.INPC raised to Buy at Deutsche Bank.LUV raised to Outperform at Credit Suisse.LUX cut to Hold at Deutsche bank.MRVL started as Neutral at Pacific Growth.MSFT coverage resumed as Neutral at B of A.MT cut to Hold at Soleil.MVL cut to Hold at Citigroup.NBIX raised to Neutral at Baird.NHP started as Buy at Cantor Fitzgerald.PLAY raised to Hold at Citigroup.SIE raised to Neutral at UBS.SUNH raised to Buy at UBS.SWFT raised to Neutral at B of A and raised to Peer Perform at Bear Stearns.TEF cut to Neutral at Merrill Lynch.TRB cut to Hold at AGEdwards.TXU cut to Hold at Citigroup.VIRL cut to Neutral at Cowen.XMSR reitr Buy at B of A.

Posted on: November 7, 2006 – 11:17 am in Newsletter, Uncategorized

GM In China Town

Stocks: (GM)(F)(TM)(HMC)What is it about China? European and American car executives think that if they say the name of the country in the same sentence with the names of their companies, their stocks will immediately go up 5%.GM’s CEO says that his company is getting bigger in China. GM is going to build more cars and components there. It would make sense given how much less expensive the labor is that the UAW-brand workers.Now, of course, Ford, Toyota, Honda, VW, and several other large car companies have the same aspirations for China, so it is starting to look like North America in terms of competition. This does not even factor in the local car companies who may have an edge because of the tendency of the Chinese government to favor the home team.Leaving aside all of the excitement about China, GM is still in deep trouble in it home market. Its share in the US seems to be stable now at about 25%. But, with it program to cut annual costs by $9 billion still not complete and concerns that the UAW may not sacrifice warm bodies forever, GM still has a long way to go.In addition to GM’s own problems in the US, Toyota continues to accelerate its effort to take market share from the Big Three. The big Japanes car-maker said it will open its seventh plant in North America within the next two years. The last anyone looked, GM was not opening any plants in Japan.GM can’t win in China if it stands on feet of clay in the US.Douglas A. McIntyre can be reached at douglasamcintyre@gmail.com. He does not own securities in companies that he writes about.

Posted on: November 7, 2006 – 10:27 am in Newsletter, Uncategorized